

The Impact of Lipid Metabolism on Human Health and Disease

Alber Fares^{1*}, George Fares² and Beshoy Fares³

¹Professor of Medical Biochemistry and Genetics, Orlando, FL, USA

²Intern Pharmacist, Advent Health, East Orlando, Florida, USA

³Anesthesiologist Assistant's Candidate, Orlando, Florida, USA

*Corresponding author: Alber Fares, Professor of Medical Biochemistry and Genetics, Orlando, FL, USA

ARTICLE INFO

Received: 📅 January 26, 2026

Published: 📅 March 09, 2026

Citation: Alber Fares, George Fares and Beshoy Fares. The Impact of Lipid Metabolism on Human Health and Disease. Biomed J Sci & Tech Res 65(1)-2026. BJSTR. MS.ID.010128.

ABSTRACT

Lipids are hydrophobic organic molecules. Due to their insolubility in water, they are compartmentalized in membranes or transported in plasma with proteins. They serve as a major energy source, create hydrophobic barriers for cells, and have regulatory roles through fat-soluble vitamins and hormones. Imbalances in lipid metabolism can lead to clinical issues like atherosclerosis and obesity. This review provides an overview of the critical roles lipids play in cellular processes, including signal transduction, membrane structure, and energy regulation. The review highlights recent advances in lipid metabolism research, emphasizing catabolism, synthesis, and signaling pathways. By synthesizing current knowledge, this work aims to delineate the distinct physiological effects of various lipid species, offering insights into potential therapeutic targets for metabolic disorders.

Keywords: Lipid; Fat; Fatty Acids; Triacylglycerol; Metabolism; Lipotoxicity

Abbreviations: TAG: Triacylglycerol; FAs: Fatty Acids; GPLs: Glycerophospholipids; TCA: Tricarboxylic Acid; LCFA: Long-Chain Fatty Acids; FFAs: Effectively Directing Free Fatty Acids; LDs: Lipid Droplets; ER: Endoplasmic Reticulum; DAGs: Diacylglycerols; FAO: FA Oxidation; FAT: FA Translocase; FABPm: Plasma Membrane FA-Binding Protein; FABPc: Cytoplasmic FABP; mAspAt: Mitochondrial Aspartate Aminotransferase; CoA: Acyl-Coenzyme A; PUFAs: Polyunsaturated FAs; TCA: The Multifunctional Enzyme FA Synthase; ACLY: Citric Acid Cycle; ATP Citrate Lyase; ACCs: Ac-CoA Carboxylases; MCD: Malonyl-CoA Decarboxylase; Elongated by Fatty Acid Elongase 5 ELOVL5; SCD: Stearoyl-CoA Desaturase; FADS2: Fatty Acid Desaturase 2; DGAT: Diglyceride Acyltransferase; SREBP-1: Sterol Regulatory Element-Binding Protein 1; GIs: Genetic Interactions; LCFA: Long-Chain Fatty Acid; PtdCho: Phosphatidylcholine and PtdIns: Phosphatidylinositol; PLP: Pyridoxal 5'-Phosphate; SPT: Serine Palmitoyl Transferase; 3KS: 3-Ketosphinganine; UPR: Unfolded Protein Response; MALDI-MS/MS (Liquid Chromatography-Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry; MAGL: Monoacylglycerol Lipase; PHD3: Prolyl-Hydroxylase 3 Protein; WAT: White Adipose Tissue; BAT: Brown Adipose Tissue; PAHSAs: Palmitic Acid Hydroxystearic Acids; LDL: Low-density lipoprotein; Atherosclerotic Cardiovascular Diseases; PI: Phosphatidylinositol; PUFAs: Omega-3 Polyunsaturated Fatty Acids

Introduction

The average U.S. adult consumes about 81 g of lipids daily, primarily triacylglycerol (TAG). Lipid digestion starts in the stomach with the help of lingual lipase, produced by tongue glands, which target triacylglycerol, especially those with short- or medium-chain fatty acids. Gastric lipase also contributes to this process. Both enzymes function optimally between pH 4 and 6 and are crucial for neonates relying on milk fat and individuals with pancreatic insufficiency, aiding in TAG breakdown when pancreatic lipases are lacking, represented in Figure 1 [1]. Dietary fats consist of a complex blend of lipids, with triglycerides making up roughly 97%. Also referred to as triacylglyc-

erols, triglycerides are esters created from glycerol and free fatty acids. Their molecular structure features three fatty acid chains linked to a glycerol backbone. These triglycerides are usually consumed in large aggregates, such as oil droplets or fat crystals [2]. Lipases are enzymes that break down triglycerides into free fatty acids (FFAs) and glycerol, found in various tissues such as the liver, adipocytes, and small intestines. They are crucial for fat digestion, absorption of fat-soluble vitamins, and understanding conditions like fat necrosis and pancreatitis. Additionally, lipases are significant in the mechanism of cholesterol-lowering medications (see Figure 2). When lipids and partially digested proteins enter the lower duodenum and jeju-

num, cells in the mucosa produce a small peptide hormone known as cholecystokinin (CCK) [1,3,4]. Since lipolytic enzymes (lipases) perform catalytic functions at the oil-water emulsion interface, which

forms between the aqueous environment of the gastrointestinal tract lumen and lipid droplets [5,6], Fats must be emulsified into micro- or nanodroplets called mixed micelles to digest [7,8].




Figure 1: Overview of lipid digestion [1].




Figure 2: Hormonal Regulation of Lipid Digestion in the Small Intestine [1].

Other enzymes that contribute to lipid digestion include hepatic lipase, endothelial lipase, lipoprotein lipases, bile salt-stimulated lipase, pancreatic lipase-related protein 2, pancreatic phospholipase A2, and carboxyl ester hydrolase; however, their roles in lipid digestion are relatively minor [9]. The digestion process begins in the mouth, where teeth grind food and mix it with saliva, initiating lipid breakdown. Once the food bolus reaches the stomach, peristalsis and hydrochloric acid further break it down, releasing and emulsifying lipids [10]. Gastric lipase partially digests dietary triglycerides in the stomach [7], but most lipid digestion occurs in the small intestine, where pancreatic lipase is essential [7,8]. Cholecystokinin (CCK) is a peptide hormone associated with the gastrointestinal (GI) system. Its receptors are found within the central nervous system [11], specifically in areas such as the hippocampus, cerebral cortex, and striatum [12]. CCK is found in the nucleus of the tractus solitarius and area postrema in the brainstem. This tissue-specific hormone shows a biphasic expression pattern, decreasing before birth and rising after. While CCK levels are low at birth, they increase with maturity. CCK is present in various tissues like thyroid C cells and the adrenal medulla. CCK receptors, CCK-1 and CCK-2, are part of the class 1 G-protein-coupled receptor family. CCK1 receptors are found in gallbladder smooth muscles and pancreatic cells, while CCK2 receptors are mainly in the stomach and pancreas [13]. Gallbladder contraction releases bile, aiding in digestion by providing bile salts and cholesterol. Pancreatic stimulation prompts enzyme secretion, while reduced gastric motility slows the release of contents into the small intestine. Secretin is released in response to low pH, prompting the pancreas and liver to release bicarbonate to neutralize intestinal contents for optimal enzyme activity. Long-chain fatty acids require emulsification for breakdown, while short- and medium-chain fatty acids are degraded in the stomach. In the small intestine, pancreatic lipases and bile salts facilitate the breakdown of fats into absorbable components, forming mixed micelles. Absorbed fats are then converted into chylomicrons, while absorption issues can lead to steatorrhea or chylomicron accumulation in the blood [1].

Cellular lipids comprise a wide array of individual molecular components, resulting in an extensive variety of lipid species, collectively referred to as the lipidome [14]. Lipid metabolism plays a vital role in numerous cellular processes essential for maintaining homeostasis, such as membrane synthesis and utilizing lipids (e.g., triacylglycerol "TAG") as energy reserves. Fatty acids are crucial lipids that form the primary structural elements of membrane lipids (including glycerophospholipids "GPLs" and sphingolipids) and function as a significant energy source through mitochondrial β -oxidation and the catabolism of the tricarboxylic acid (TCA) cycle (citric acid cycle) [15]. Excessive amounts of circulating lipids have been associated with metabolic diseases [16,17] and cancer [18]. The adverse effects resulting from prolonged exposure to high lipid levels are termed "lipotoxicity" [19,20]. This term was first introduced by Roger Unger (1924-2020) and his team to describe the inhibition of pancreatic β -cell function and the onset of type 2 diabetes in rats with lipid overload in their pancreatic islets [21]. The molecular mechanisms that contribute to lipotoxicity encompass endoplasmic reticulum (ER) stress, oxidative stress, mitochondrial dysfunction, impaired autophagy, and inflammation [19]. Metabolic disorders characterized by an imbalance between the uptake or synthesis and consumption of fatty acids lead to the accumulation of lipid intermediates within cells, causing dysfunction and cell death in various tissues, including the kidneys, brain, skeletal muscle, and heart. According to [22] effectively directing free fatty acids towards structural lipids, lipid droplets (LDs), or mitochondria for β -oxidation can help alleviate the detrimental effects of lipid accumulation. The processes of fatty acid synthesis, uptake, degradation, and signaling in both homeostatic and disease contexts shown in Figure 3.

Over 40,000 lipids have been identified across various kingdoms of life, yet our comprehension of the functions many of these lipids serve in cell biology and physiology remains incomplete [15]. Lipids are complex molecules formed from simpler components through enzymatic processes. Typically, each lipid features a head group with a distinct chemical makeup, esterified to hydrophobic tails made of fatty acyl chains or sphingoid bases [23].




Figure 3: Outlines lipid metabolism, highlighting the need for a systematic approach to differentiate between beneficial and lipotoxic lipids. Bioactive lipids regulate functions like proliferation, storage, and energy production, while lipotoxic lipids can cause cell death and metabolic disorders. Understanding these roles is crucial for maintaining metabolic homeostasis [15].

Classification of Lipids

Lipids are vital compounds with key biological roles, including cell membrane structure, energy storage, and signaling. The study of lipids (lipidomics) is essential for understanding cellular functions and diseases, particularly in the context of genomics and proteomics.

The “lipidome” represents the complete lipid profile of a cell or organism and is part of the broader “metabolome.” Advances in analytical technologies, especially mass spectrometry, have propelled lipidomics, highlighting its significance in various metabolic diseases. A membrane lipid consists of fundamental components [24]:

Fatty Acids

The biological roles of different lipid classes are influenced by their head groups. Fatty acids (FAs) play diverse and crucial roles, including:

- Serving as building blocks in cells
- Acting as vital biochemical intermediates
- Determining membrane properties
- Modulating cellular signaling pathways
- Functioning as a fuel source

Fatty acids are made up of long chains of carbon atoms, featuring a carboxylic acid (-COOH) group at the first carbon and a methyl (CH₃) group at the end of the chain. The carboxylic acid group plays a crucial role in bonding the fatty acid to other lipid components. In humans, fatty acids typically range from 12 to 24 carbons in length, with most having an even number of carbon atoms. They can contain: Single bonds (C-C), Double bonds (C=C) and Triple bonds (C≡C). Saturated fatty acids have only single carbon-carbon bonds and are fully bonded to hydrogen, while unsaturated fatty acids contain at least one double bond, allowing for more hydrogen bonding. If there are multiple double bonds, they are termed polyunsaturated. Double bonds can be in a “kinked” cis configuration or a linear trans configuration [25].

Glycerol

Glycerol is a three-carbon molecule with hydroxyl groups (-COOH) that bond with fatty acids to form diacylglycerol and triacylglycerol. The number and type of double bonds in fatty acids affect their melting temperatures: saturated fatty acids range from 44°C to 77°C, while unsaturated fatty acids range from 13°C to -50°C, decreasing further with more double bonds due to disorganized packing. This is seen in the melting temperatures of butter (saturated) versus margarine (unsaturated). Trans fatty acids, having a linear structure, complicate metabolism and may contribute to heart disease. Unsaturated fats, especially cis polyunsaturated fats, are recommended for better health to help prevent coronary heart disease [25,26].

Essential Fatty Acids

Certain fatty acids are considered essential. Notably, two essential fatty acids, linoleate and linolenate, contain double bonds at the sixth and third carbon atoms from the methyl end of their chains, respectively, and are necessary for producing specific 20-carbon fatty acids with double bonds. These are known as omega-6 (ω-6) and omega-3 (ω-3) fatty acids. Humans cannot produce double bonds at these positions, so these essential fatty acids must be obtained from dietary sources, particularly vegetable oils. Arachidonate, a 20-carbon chain with four cis double bonds, is also an essential fatty acid involved in various biological functions. Recently, longer-chain ω-3 fatty acids

have been linked to a reduced risk of heart attacks and strokes; thus, supplements and certain food products containing these fatty acids are now available. Interestingly, excessive intake of ω-6 fatty acids has been associated with an increased risk of heart attacks, strokes, some cancers, and even depression [25,27].

Head Group

The final component of a lipid molecule varies among different lipid types and, along with the two specific fatty acids, defines each lipid. This third part is often referred to as the “head group,” aptly named if one imagines the end methyl group of the fatty acid chains as the tail of the lipid molecule. Most biological membrane lipids contain a phosphate group (PO₄³⁻) attached to the third glycerol carbon, categorizing them as phospholipids. Often, an additional molecule (several common examples found in humans is attached to the phosphate group, creating the final head group of the lipid molecule). This head group is typically charged, making it hydrophilic and drawn to water—a critical quality for forming biological membranes and for various lipid functions [25]. Fatty acids are the foundational components of all lipids, acting as precursors for synthesizing other lipid types, including glycerolipids, glycerophospholipids (GPLs), sphingolipids, sterols, and saccharolipids [28]. Imbalances between fatty acids uptake and oxidation can result in the buildup of long-chain fatty acids. These fatty acids are then incorporated into triglycerides (TAGs), phospholipids, and various other lipid species [22]. Ceramides, diacylglycerols (DAGs), and acyl-carnitines, which regulate intracellular signaling cascades and metabolism [29,30] are generally regarded as toxic signaling lipids [22]. Additionally, defective mitochondrial FAs oxidation (FAO) results in an increase of medium-chain acyl-carnitines, another toxic species [31]. Exploring the varied roles of lipids, particularly regarding metabolic diseases and cancer, provides a pathway to understanding lipid-mediated toxicity.

Fatty Acid and Triacylglycerol Metabolism

Generally, fatty acids, linear hydrocarbons with a terminal carboxyl group, can be saturated or unsaturated. Essential fatty acids like linoleic and α-linolenic acids must be obtained through diet. In the liver, fatty acids are synthesized from excess carbohydrates and proteins using acetyl CoA, ATP, and NADPH. The process begins with acetyl CoA carboxylase, which is regulated by citrate and long-chain fatty acyl CoA, and is influenced by insulin and AMPK. Fatty acids synthase converts acetyl CoA and malonyl CoA into palmitoyl CoA. Energy from stored triacylglycerol is released by hormone-sensitive lipase in adipose cells, with fatty acids transported via serum albumin to the liver for oxidation. Glycerol acts as a gluconeogenic precursor. β-oxidation occurs in mitochondria, needing the carnitine shuttle for long-chain fatty acids, while malonyl CoA inhibits transport. This process produces acetyl CoA, NADH, and FADH₂. Medium-chain fatty acyl CoA dehydrogenase deficiency can cause metabolic issues. Odd-chain fatty acids yield propionyl CoA, which converts to succinyl CoA for

gluconeogenesis. Fatty acid oxidation also occurs in peroxisomes and the endoplasmic reticulum (ER), with liver mitochondria generating ketone bodies during fasting, which can lead to ketoacidosis in un-

controlled type 1 diabetes [1]. Figure 4 illustrates the metabolic pathways of fatty acid synthesis and degradation, and their relationship to carbohydrate metabolism.




Figure 4: The metabolic pathways of fatty acid synthesis and degradation [1].

Complex Lipid Metabolism

Phospholipids are polar compounds (Figure 5) formed from an alcohol and either diacylglycerol or sphingosine, with key types including sphingomyelin, crucial for cell membranes. They play roles in lung surfactants, with dipalmitoyl phosphatidylcholine being a major component. Phosphatidylinositol (PI) serves as a reservoir for

arachidonic acid, which, when phosphorylated, produces PIP2 that mediates intracellular calcium mobilization. Glycolipids, derived from ceramides, are vital in brain membranes and are antigenic. Prostaglandins, thromboxane's, and leukotrienes act as inflammatory mediators, derived from linoleic acid and arachidonic acid. Their synthesis involves enzymes like COX, with NSAIDs inhibiting their production [32].




Figure 5:

- A. Structures of some glycerophospholipids,
 B. Phosphatidic acid,
 P in circle= phosphate, PO₄⁻ [1].

Cholesterol and Steroid Metabolism

Cholesterol is a hydrophobic compound vital for human health, synthesized mainly in the liver, intestine, and adrenal cortex, with its production driven by acetate and NADPH. The key regulatory enzyme, HMG CoA reductase, is influenced by various factors such as insulin and glucagon levels. Statins inhibit this enzyme to lowering plasma

cholesterol. Cholesterol is eliminated through bile salts, which are produced from cholesterol and help emulsify fats. Bile acids are reabsorbed in the intestine and returned to the liver. Lipoproteins, such as chylomicrons and VLDL, transport lipids throughout the body, while HDL plays roles in cholesterol transport and metabolism. Cholesterol serves as a precursor for steroid hormones, which interact with specific receptors to regulate gene expression [33] (See Figure 6).




Figure 6: Summarizes the main sources of liver cholesterol and its exit routes from the liver [1].

Cellular Uptake of Fatty Acids

The cellular uptake of fatty acids is crucial for metabolic regulation. Although FAs can naturally diffuse through phospholipid bilayers, the majority of FAs uptake in mammalian cells is supported by integral or membrane-associated proteins. Various transporters from multiple classes mediate cellular FAs uptake [34-37], including:

- Scavenger receptor CD36 (FA translocase "FAT")
- Plasma membrane FA-binding protein (FABPpm)
- Six FA transport proteins (FATPs; solute carrier family SLC27A1-6)

Once FAs reach the inner side of the membrane, they bind to cytoplasmic FABP (FABPc) before entering various metabolic or signaling pathways. Interestingly, research has revealed that FABPpm and mitochondrial aspartate aminotransferase (mAspAt) are the same proteins involved in amino acid metabolism [38,39]. Moreover, FAs are activated by a group of acyl-coenzyme A (CoA) synthetase (ACS) enzymes that catalyze the conversion of free fatty acids (FFAs) into CoA esters [40]. This CoA conjugation helps maintain the concentra-

tion gradient by actively drawing FAs into the cell. Additionally, FATPs are a family of membrane proteins that facilitate the import of long-chain FAs (LCFAs) and leverage ACS activity to regulate intracellular polyunsaturated FAs (PUFAs) [41]. Among the six FATP/SLC27A family members, the overexpression of FATP1 in 3T3-L1 cells-a mouse embryonic fibroblast cell line capable of differentiating into adipocyte-like cells-leads to the uptake of palmitic acid, oleic acid, and arachidonic acid without any specific preference for these FAs [42]. Subcellular fractionation studies indicate that FATP is situated in the plasma membrane, facilitating the transport of LCFAs into the cell for energy substrate utilization [15].

Fatty Acids Synthesis

FAs synthesis is an anabolic process responsible for creating a variety of lipid species. The multifunctional enzyme FA synthase (FASN) plays a crucial role by converting dietary carbohydrates into long-chain saturated fatty acids, primarily focusing on the 16-carbon palmitate. This conversion utilizes acetyl-CoA (Ac-CoA) as a primer (see Figure 7). FASN contributes to the supply of additional lipids, which support membrane structure and facilitate cytosolic signaling.




Figure 7: Lipid metabolism involves both catabolic and anabolic processes, including: Uptake of lipids via transport proteins. lipid metabolism pathways coordinate to regulate cellular metabolic states [15].

Several metabolic enzymes participate in transforming carbon from citrate within the citric acid cycle (TCA) into bioactive FAs. ATP citrate lyase (ACLY) converts citrate generated in the mitochondrial TCA cycle into Ac-CoA in the cytosol, serving as a precursor for FA synthesis [43]. Other key molecular components include Ac-CoA carboxylases (ACCs), which produce malonyl-CoA. Additionally, malonyl-CoA decarboxylase (MCD) transforms malonyl-CoA back into Ac-CoA, effectively reversing the ACC-catalyzed reaction [44]. Through a series of condensations involving seven malonyl-CoA molecules and one priming Ac-CoA, FASN generates palmitate, the primary product of FAs synthesis. This 16-carbon saturated fatty acid is subsequently activated by acyl-CoA synthetase (ACS), elongated by fatty acid elongase 5 (ELOVL5), and desaturated by stearoyl-CoA desaturase (SCD) and fatty acid desaturase 2 (FADS2), resulting in a range of molecules with varying lengths and degrees of saturation [45,46].

The synthesized fats are stored as triglycerides (TGs) within cells. Diglyceride acyltransferase (DGAT) is integral to the TG synthesis pathway, converting diacylglycerol (DAG) into triacylglycerols (TAGs). DGAT enzymes catalyze the final step in the known TG synthesis pathways. Although the two DGAT enzymes differ in protein sequences, they both utilize fatty acyl-CoA substrates [47]. The TGs produced by DGAT enzymes are stored in cytosolic lipid droplets or in organs like the liver and small intestine, where they are released as compo-

nents of lipoproteins. Both DGAT enzymes are expressed ubiquitously across tissues and are especially prevalent in organs involved in triglyceride metabolism, including adipose tissue and the liver [48]. Fatty acids synthesis enzymes are governed at the transcriptional level by sterol regulatory element-binding protein 1 (SREBP-1) transcription factors [49]. A recent genome-wide CRISPR screen systematically identified genetic interactions (GIs) in human HAP1 cells, a near-haploid cell line derived from chronic myelogenous leukemia (CML), to explore how cells adapt to the absence of de novo FA synthesis [50]. Figure 7 illustrates:

- The transport of fatty acids into mitochondria for oxidation, resulting in the production of acetyl-CoA for ATP.
- The entry of glucose into the TCA cycle via pyruvate and acetyl-CoA.
- The uptake of acetate through MCT, leading to an increase in cytosolic acetyl-CoA levels.
- The impact of acetyl-CoA on histone and protein acetylation, facilitating epigenetic modifications.
- The oxidation of VLCFAs and BRCFAs in peroxisomes, which supports TCA metabolism.
- The export of citrate from the TCA cycle for de novo lipogenesis, which results in the synthesis of fatty acids and cholesterol.

- The synthesis of fatty acids from malonyl-CoA, yielding palmitate, which can be converted into MUFAs and PUFAs.
- The storage of long-chain fatty acids as triglycerides, with palmitate transforming into CDP-DAG and diacylglycerol for phospholipid synthesis, essential for cell membrane structure.

Cells with a loss-of-function mutation in FASN, the enzyme responsible for long-chain fatty acid (LCFA) formation, demonstrate a significant reliance on lipid uptake, evidenced by negative GLs with genes associated with the low-density lipoprotein receptor signaling pathway [50]. Notably, a previously unrecognized role for C12orf49 has emerged in regulating exogenous lipid uptake via the sterol regulatory element-binding protein SREBF2. This study illustrates how pooled genome-wide CRISPR screens can identify novel metabolic targets in human cells. While most normal cells favor extracellular lipids for synthesizing new structural lipids, cancer cells increase de novo FA synthesis to support proliferation in lipid-poor environments lacking extracellular lipids [51]. SREBP enhances the synthesis of phospholipids, triglycerides (TAG), and cholesterol, thereby promoting the survival and growth of cancer cells [52,53]. Cancer progression is further accelerated by SREBP-1 signaling, with the RNA-binding protein LIN-28 speeding up de novo FA synthesis and facilitating the conversion from saturated to unsaturated fatty acids [54]. Together with essential fatty acids like linolenic acid obtained from the diet, they create a complex array of substrates for synthesizing FA-containing lipids.

FASN, along with membrane receptor tyrosine kinases (RTKs) and the serine/threonine kinase mTOR, plays a crucial role in regulating survival signaling by providing second messenger signaling lipids [51]. Consequently, de novo FAs synthesis leads to the production of diverse lipids that play critical roles in cellular signaling and lipid homeostasis. For a more in-depth exploration of FA dysregulation in cancer cells, we recommend a recent comprehensive review on the topic [55]. Fatty acids engage with various metabolic enzymes to integrate into complex lipid species, such as diacylglycerols (DAGs) and triacylglycerols (TAGs), or to be transformed into phosphoglycerates like phosphatidic acid (PA), phosphatidylethanolamine (PE), and phosphatidylserine (PS) [56,57] (Figure 4). The acyl groups of fatty acids, especially the stearyl groups present in mammalian cells, play a significant role in shaping the diversity of phosphatidylcholine (PtdCho) and phosphatidylinositol (PtdIns) [58,59]. PtdIns are recognized as some of the most well-studied secondary messengers in signal transduction pathways. Through phosphorylation, PtdIns can be converted into various phosphoinositide species, including PtdIns 4,5-bisphosphate and PtdIns (3,4,5)-trisphosphate (PIP2/3) [60]. PIP3 activates AKT, which triggers pro-tumorigenic signaling via phosphoinositide-dependent kinase 1 (PDK1), tuberous sclerosis complex (TSC) 1/2, and mTORC2 [57].

Additionally, FAs can be utilized for the de novo synthesis of ceramide in the endoplasmic reticulum (ER). The process begins with the condensation of the activated C16 FA palmitoyl-CoA and the amino

acid L-serine, catalyzed by pyridoxal 5'-phosphate (PLP)-dependent serine palmitoyl transferase (SPT). This reaction yields 3-ketosphinganine (3KS), which can be quickly reduced to sphingosine (dihydrosphingosine) by 3KS reductase (KDSR) in a NADPH-dependent reaction [61]. FAs synthesis is stimulated by hypoxia-inducible factor (HIF) signaling [62]. HIF represses carnitine palmitoyl transferase 1 (CPT1), which decreases FAs transport into mitochondria and redirects FAs toward lipid droplets (LDs) for storage [63]. Both HIF-1 α and HIF-2 α are upregulated in response to ER stress [64] which promotes the formation of LDs to mitigate cytotoxic ER stress responses [65].

Lipotoxicity and Metabolic Regulation

An increase in LDs within cells is often linked to lipotoxicity and metabolic alterations that lead to cellular dysfunction. The composition and catabolism of LDs serve as crucial regulatory points that integrate physiological inputs, such as dietary lipids and lipolytic signals, to synchronize cellular signaling and metabolism. LDs help maintain lipid homeostasis, prevent lipotoxicity, and generate ATP by degrading stored lipids during metabolic stress [66]. Furthermore, the inhibition of SREBP or restriction of fatty acid synthase (FASN) can activate the HIF-1 α signaling pathway and the unfolded protein response (UPR) [52]. In situations of energy deficiency-mediated stress, HIF signaling pathways work in conjunction with AMP-activated protein kinase (AMPK) and mTOR to compensate for FASN limitations and activate lipid metabolism, thus alleviating lipid-mediated ER stress.

FASN Antagonists as a Cancer Treatment

FASN antagonists are gaining attention as a potential therapeutic strategy for cancer treatment. Advanced techniques like MALDI-MS/MS (liquid chromatography-matrix-assisted laser desorption/ionization mass spectrometry) ease enhanced proteome analysis [67]. Mass spectrometry applications show that FASN inhibitors, such as C75 and G28UCM, increase PUFAs while decreasing signaling lipids like DAG and PIP3 in ovarian cancer cell lines [62]. According to [62,67-70] affects several downstream targets, indicating that a deeper understanding of pathway interactions could improve drug target efficacy by impacting multiple pathways. Specifically, FASN inhibition influences ERBB-PI3K-mTORC1 activity by:

- Blocking phosphorylation of the EGF receptor/ERBB/HER
- Inhibiting GRB2-EGF receptor recruitment
- Suppressing PI3K-AKT signaling

Furthermore, fatty acids synthesis is heightened in metastatic breast cancer, particularly in the brain. This phenomenon arises as an adaptation to the lower lipid availability in the brain compared to other tissues, leading to a specific reliance on fatty acid synthesis for breast tumors developing in the brain. FASN inhibition notably reduces the growth of human EGF receptor 2-positive breast tumors in the brain, highlighting the potential for new cancer targets based on different nutrient availability across metastatic sites [71].

FABP5 serves as an intracellular chaperone that transports cytosolic fatty acids to nuclear receptors, promoting metastasis. Both FASN and monoacylglycerol lipase (MAGL) are crucial for activating nuclear receptors, and prostate cancer metastasis significantly relies on the co-expression of FABP5 [72]. Additionally, the expression level of FASN influences PI3K/AKT signaling through phosphatase and tensing homolog deleted on chromosome 10 (PTEN) [73]. According to [74] greater insight into these intersecting pathways will enhance the design of effective FASN inhibitors that manage multiple interconnected targets. Besides HIF-dependent pathways, fatty acids synthesis is also regulated by various metabolic enzymes. Lipid biosynthesis and oxidation are governed by a master regulator of fatty acid metabolism, ACC, which converts Ac-CoA to malonyl-CoA. This conversion serves as a precursor for fat synthesis while inhibiting fatty acid oxidation.

- ACC1 is found in the cytosol and promotes fatty acid production.
- ACC2, located in the mitochondrial outer membrane, generates malonyl-CoA to inhibit FATP CPT1

Cellular stress has a direct impact on enzymatic activities related to ACC and regulates fatty acid metabolism. Under energy stress conditions, AMPK activates both fatty acid synthesis and catabolism by inhibiting both ACCs [75]. Conversely, in nutrient-rich conditions,

AMPK is downregulated and ceases to repress ACC1 and ACC2. Additionally, ACC2 is influenced by post-translational modifications; for instance, prolyl-hydroxylase 3 protein (PHD3) creates a metabolic barrier to fatty acid utilization by hydroxylating and activating ACC2 [73, 76]. Thus, ACC acts as a signaling hub that senses nutrient levels and adjusts anabolic versus catabolic fatty acid metabolism accordingly. In acute myeloid leukemia, decreased PHD3 levels lead to a reliance on fats, which can be targeted by fatty acid oxidation inhibitors. Beyond AML, many cancer cells utilize fatty acid synthesis to promote proliferation [15].

Lipotoxicity Across Diverse Organ Systems

Impairments in fatty acids metabolism significantly impact on various human diseases. Recent advancements using CRISPR-based genetic screens and unbiased lipidomics have unveiled new ways to investigate the enzymes that manage how FAs integrate into membrane and storage glycerolipids. The accumulation of lipids within tissues is increasingly acknowledged as a factor contributing to cellular dysfunction. Many cells across different organ systems struggle to cope with excess lipid loads, and the mechanisms through which surplus lipids induce cellular injury, or lipotoxicity, are being explored in the kidney, liver, heart, skeletal muscle, bone, pancreas, and brain [77] (see Figure 8).




Figure 8: Under excess nutrient conditions, lipolysis decreases, promoting triglyceride storage in adipose tissue, while glucose oxidation rises in muscle cells. In fasting, lipolysis and fatty acid oxidation increase for energy in adipose and muscle cells, respectively. Metabolic changes also occur in the brain, heart, liver, pancreas, kidney, and adipose tissue [15].

Saturated FAs are believed to be particularly detrimental, triggering a variety of harmful cellular responses such as:

- Apoptosis
- Inflammation
- Ceramide formation
- Reactive oxygen species (ROS)
- Small nucleolar RNAs
- Endoplasmic reticulum (ER) stress

A key focus in this field is identifying bioactive lipid species that influence the lipotoxic cellular response [77].

Lipid Accumulation in Adipose Tissue

Adipose tissue plays a crucial role in regulating energy homeostasis, and its dysfunction leads to energy imbalances due to inappropriate lipid loads in peripheral tissues. Adipocytes serve as energy reservoirs, sensing energy demands and releasing paracrine factors to regulate other metabolic tissues. Mammals possess two types of adipose tissue [78]:

- White adipose tissue (WAT), which stores excess energy.
- Brown adipose tissue (BAT), which expends excess energy as heat.

A primary function of WAT is to release non-esterified fatty acids (NEFAs) into the bloodstream during times of energy need. Recent research has focused on the byproducts of lipid metabolism that affect adipocyte function. Short-chain fatty acids (SCFAs) and TCA cycle metabolites are emerging as key players that link lipogenesis to WAT energy balance. SCFAs such as acetate, butyrate, and propionate inhibit lipolysis and promote adipogenesis in WAT, while also providing substrates for glucose and lipid synthesis. They act on G protein-coupled receptors (GPR41 and GPR43) to reduce lipolysis and lower plasma levels of free fatty acids (FFAs) [78].

Using extremely sensitive mass spectrometry-based proteomics on human adipocytes, researchers identified 471 secreted proteins, including hormones, growth factors, and extracellular matrix proteins, that are differentially regulated between BAT and WAT. Notably, brown and white adipocytes exhibit distinct secretory profiles and metabolic functions. The mammalian ependymin-related protein 1 (EPDR1) is selectively secreted by brown adipocytes and is essential for promoting the development of functional thermogenic adipocytes by activating UCP1 expression. This recent analysis of the secretome in mature white and brown adipocytes has highlighted crucial regulators of human metabolism [79].

Lipid Accumulation in the Kidney

Extensive research in animal models has established a connection between kidney dysfunction and lipid accumulation in various metabolic diseases, such as obesity, metabolic syndrome, diabetes mellitus, chronic kidney disease, and acute kidney injury [80-82]. Hu-

man clinical studies have also reported lipid accumulation and kidney dysfunction associated with conditions such as focal segmental glomerulosclerosis (FSGS), minimal change disease, Fabry's disease, and lipoprotein glomerulopathy [83]. The kidney utilizes multiple substrates for energy, depending on their availability [80-82]. Substrate utilization varies across different kidney regions based on energy demands [83]. The proximal tubules, which have a high energy requirement second only to cardiac myocytes-exhibit limited glycolytic capacity. Instead, they predominantly rely on mitochondrial β -oxidation of free fatty acids (FFAs) for optimal ATP production [84-86]. Recent findings suggest that in diabetic kidney disease, the proximal tubule expresses kidney injury molecule (KIM)-1, which facilitates the uptake of palmitate (PA) and leads to increased tubule injury characterized by DNA damage, interstitial inflammation, and fibrosis [87]. The small-molecule inhibitor of KIM-1, TW-37, has demonstrated the ability to alleviate kidney inflammation and fibrosis.

These studies underline the potential of targeting small molecules upstream of fatty acid oxidation (FAO) as a novel therapeutic strategy for kidney injury. [15] states that the kidney responds to lipid toxicity by regulating regulators involved in lipid peroxidation and accumulating toxic metabolites like fatty acyl-CoA, diacylglycerol (DAG), and ceramides. Lipotoxic cellular dysfunction results in the production of reactive oxygen species (ROS), organelle damage, disruption of intracellular signaling pathways, and the release of pro-inflammatory and pro-fibrotic factors, ultimately leading to lipid-induced apoptosis. Lipid peroxidation occurs when oxidants, such as free radicals, attack lipids containing carbon-carbon double bonds, particularly polyunsaturated fatty acids (PUFAs).

Although numerous studies indicate that PUFAs can reduce kidney disease by lowering triglycerides (TGs) and inflammation, it is theorized that PUFAs may be converted into oxidized lipids by lipoxygenases (LOX), cyclooxygenases (COX), and cytochrome P450 enzymes (CYP) [88]. The kidney is particularly vulnerable to changes in the gene expression of sterol regulatory element-binding proteins (SREBPs) induced by diabetes. This leads to triglyceride accumulation, mesangial expansion, and glomerulosclerosis [89]. This suggests that the activation of renal SREBP-1 leads to changes in renal lipid metabolism, indicating that renal lipid accumulation plays a significant role in the pathogenesis of diabetic nephropathy [15]. Lipid accumulation is a major factor contributing to diabetic kidney disease, which is currently the fastest-growing cause of kidney failure globally. Podocytes, essential components of the kidney filter, are highly specialized epithelial cells that are particularly vulnerable to lipid accumulation and toxicity [90,91]. Coenzyme Q10 (CoQ), a lipid found in all cellular membranes, offers protection against PUFA-mediated lipid peroxidation. In the context of mitochondrial dysfunction, the lack of protection from lipid peroxidation makes cells more susceptible to death [79]. Increased lipid peroxidation, indicated by elevated glutathione peroxidase 4 (GPX4), has been observed in podocytes of

CoQ-deficient mice [92]. Furthermore, the loss of GPX4 can trigger ferroptosis in the kidney, contributing to renal degeneration [93].

Recent research efforts to explore the connection between kidney disease, PUFAs, and dysregulated pathways in podocytes have utilized single-nucleus RNA sequencing (sNuc-Seq) along with integrated metabolomics and transcriptomics to identify a therapeutically relevant Braf/MAPK pathway [92]. Additionally, junctional adhesion molecule-like protein (JAML) is expressed in podocytes and is induced under diabetic conditions. Deleting JAML specifically in podocytes has been shown to reduce podocyte injury and proteinuria in two different models of diabetic mice [94]. Junctional adhesion molecules, part of an immunoglobulin subfamily, are increasingly recognized for their role in lipid metabolism. For instance, Jam-A knockout mice fed high-saturated fat, fructose, and cholesterol diet (HFCD) develop severe non-alcoholic steatohepatitis [95]. Utilizing LC/MS-based lipidomics analysis revealed that JAML deletion in podocytes lowers levels of lipids, including FFAs, cholesteryl esters, and phosphatidylcholines (PtdChos) [94]. JAML regulates podocyte lipid metabolism through SIRT1-mediated SREBP-1 signaling and is found at elevated levels in the glomeruli of patients with kidney disease.

The Roles of the Liver, Bone, and Skeletal Muscle in Lipotoxicity

According to [15] fatty acids are transported to the liver via the bloodstream following the lipolysis of triglycerides (TGs) in adipose tissue. In the liver, FAs bind to FABP1 and undergo mitochondrial β -oxidation. Conditions such as obesity and type 2 diabetes often led to excessive fat accumulation in the liver, commonly referred to as non-alcoholic fatty liver disease (NAFLD). The primary genetic factors associated with NAFLD include PNPLA3, HSD17B13, and TM6SF2, with liver steatosis arising from the dysregulation of pathways that govern de novo lipogenesis and fat catabolism. Recent findings indicate that a decrease in the activity of lysosomal acid lipase (LAL), a crucial enzyme for intracellular fat breakdown, is clinically significant for NAFLD patients [96]. Advances in high-throughput sequencing technology have revealed potential gene candidates influencing fat deposition.

- FABP1 is a liver-specific fatty acid-binding protein that plays vital roles in the liver's lipid metabolism. Its knockdown prevents lipid accumulation in hepatocytes [97]. FABP1 regulates fat deposition through PPAR signaling and fatty acid biosynthesis [98].
- Palmitic acid hydroxystearic acids (PAHSAs) are endogenous lipids known for their anti-diabetic and anti-inflammatory properties. Chronic PAHSA treatment enhances insulin-stimulated glucose uptake in glycolytic muscle and heart tissues of high-fat diet-fed mice by improving hepatic insulin sensitivity and reducing lipolysis in adipose tissue [99]. Furthermore, PAHSAs activate GPR40 receptors, which help regulate glucose tolerance and insulin sensitivity [100].

Beyond metabolic systems, bones also play a significant role in eliminating circulating lipoproteins and non-esterified fatty acids (NEFAs) [101]. Notably, long-chain fatty acid oxidation influences postnatal bone development by modifying fatty acid utilization. Eicosapentaenoic acid (EPA; a long-chain polyunsaturated n-3 fatty acid) alters substrate cycling in human skeletal muscle cells by affecting the lipolysis rate of intracellular TAG and enhancing the re-esterification of fatty acids, thereby increasing fatty acid turnover [102].

Lipids and Cardiovascular Function

The heart has the highest caloric demand and performs extensive oxidation of fatty acids [22], efficiently acquiring lipids from circulating NEFAs and esterified fatty acids bound to lipoproteins. Lipid energy metabolism is critical for heart health, particularly concerning diseases like heart failure and ischemia. Strong clinical evidence links lipid oxidation and inflammatory responses to cardiovascular diseases. Polyunsaturated fatty acids (PUFAs) influence the levels of phospholipids and cholesterol esters in lipoproteins during atherosclerosis development [103]. Free radical lipids and altered lipoproteins produced from oxidized lipid peroxidation are crucial in influencing inflammatory responses [104,105]. Increased lipid availability exacerbates ischemia-induced cardiac dysfunction and reduces myocardial mitochondrial efficiency. This condition leads to greater myocardial FA-linked respiration and oxidative stress, while mitochondrial efficiency declines, heightening susceptibility to ischemia-related cardiac dysfunction [106].

Cell death occurs through various mechanisms, with ferroptosis—a programmed iron-dependent cell death—being driven by lipid membrane damage in ischemia/reperfusion-induced cardiomyopathy, alongside lipid peroxidation. Recent studies suggest that free iron accumulation in mitochondria can induce oxidative stress and ferroptosis, contributing to heart damage [107]. During myocardial infarction (MI), the glutathione metabolic pathway and reactive oxygen species (ROS) pathway are significantly downregulated [108]. Notably, GPX4, which protects against ferroptosis, is also downregulated during MI. Moreover, oxidized phospholipids promote inflammation in global myocardial ischemia/reperfusion injury. The cytokine IL-10 serves an anti-inflammatory function and regulates the production of oxidized phosphatidylcholines in cardiomyocytes, helping to reduce inflammation and cell death [109]. Lipid levels and composition in patient blood during MI can predict complication risks [110]. Sphingolipids serve as biomarkers for recurrence and mortality following MI [111].

Ceramides, a type of simple membrane sphingolipid that forms the backbone of complex sphingolipids, can trigger programmed cell death when present at high cellular levels [112]. Research indicates that ceramide levels are elevated in human heart tissues during acute MI [111]. Within 24 hours post-MI, 30% of genes involved in sphingolipid metabolism are significantly upregulated, resulting in increased levels of C16-ceramide, C20-ceramide, C20:1-ceramide, and C24-ce-

ramide. In hypoxic conditions resembling MI, several inhibitors can limit ceramide degradation, including the pan-ceramidase inhibitor B13 and the acid ceramidase-specific inhibitor ARN14974. Additionally, a pan-sphingosine kinase inhibitor (SK1-II) notably increases the levels of cardiomyocyte cell death. Alterations in sphingolipid metabolism by ceramidase, which hydrolyzes pro-apoptotic ceramide and generates sphingosine, are essential for managing ceramide levels and cell survival in ischemic heart disease [111].

Transcriptomic and protein analyses reveal that modifying ceramide metabolism through chemical inhibitors of sphingolipid metabolism can confer cardio protection following MI. Furthermore, the expression of microsomal TG transport protein (MTTP) is linked to structural and perfusion abnormalities in patients with ischemic heart disease, indicating that TGs are crucial for cardiac function in relation to ischemic events [113]. Decreased levels of fatty acid oxidation are commonly associated with heart failure [114]. Genetic overexpression of PPAR α in the heart replicates the characteristics of lipotoxic cardiomyopathy, while knockdown diminishes this phenotype [115]. PPAR α is a nuclear receptor transcription factor that regulates the expression of genes involved in fatty acid metabolism, including uptake, storage, and oxidation. Different fatty acids, such as saturated FAs (including palmitic acid), monounsaturated FAs (like oleic acid), and polyunsaturated FAs (such as linoleic acid), have distinct effects on metabolic diseases [116]. Current research focuses on the influence of various FAs on the GSK-3 α -PPAR α signaling pathways. Notably, palmitic acid enhances PPAR α activity, but knocking down GSK-3 α negates this increase [117]. The functional role of PPAR α phosphorylation impacts energy metabolism; specifically, PPAR α -S280D increases the expression of genes related to fatty acid uptake and pyruvate dehydrogenase kinase 4 (PDK4), which inactivates the PDH complex and inhibits glucose oxidation.

Lipid-Immune Interactions

Different fatty acids (FAs) and lipids have varying effects on immune cell subsets. Omega-3 polyunsaturated fatty acids (PUFAs) exhibit strong immunomodulatory properties, playing a significant role in the regulation of inflammatory and autoimmune diseases such as arthritis, Crohn's disease, ulcerative colitis, and lupus erythematosus [118].

- PUFAs are known to suppress the production of interleukin-1 (IL-1) and the expression of COX-2 mRNA, which is induced by IL-1.
- Additionally, alpha-linolenic acid (ALA), a precursor to omega-3 compounds, increases the secretion of pro-inflammatory cytokines (IL-1, IL-2, and tumor necrosis factor-alpha).
- Alongside these pro-inflammatory mediators, ALA has been recognized for its ability to suppress prostaglandins and leukotrienes while promoting anti-inflammatory and resolving functions [118-120].

PUFAs and related fatty acids hold promise as potential targets for treating inflammatory diseases.

[82] The immune system plays a pivotal role in eliminating cancerous cells. The interaction between immune cells and cancer is highlighted by how tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic challenges within the tumor microenvironment (TME), providing a pathway to combat tumor progression.

- T cells exhibit a degree of metabolic flexibility.
- CD36, located in the plasma membrane, is crucial for facilitating the uptake of exogenous fatty acids. The upregulation of CD36 in intratumoral regulatory T (Treg) cells significantly influences tumor progression and T cell function.
- In TMEs with low glucose levels, CD8+ T cells enhance PPAR-alpha signaling and fatty acid catabolism under hypoglycemic and hypoxic conditions to partially maintain effector functions [82].

Notably, the metabolic reprogramming of T cells using a PPAR-alpha agonist has been shown to inhibit tumor growth, an effect that is further amplified in conjunction with PD-1 inhibition [121]. Given that fatty acid oxidation (FAO) is essential for the differentiation of Treg cells, inhibiting FAO could hinder the buildup of this immunosuppressive T cell population [122]. These findings suggest that lipid metabolism offers exciting opportunities to influence the TME and specific immune cell populations.

Metabolic rewiring has been associated with a protumor phenotype in tumor-associated macrophages, extending beyond T cells. The alternative (M2) activation of macrophages relies on fat oxidation. Triacylglycerol (TAG) substrates are absorbed via the scavenger receptor CD36, and their lipolysis by lysosomal acid lipase (LAL) results in prolonged survival and M2 activation in ovarian cancer. This indicates that inhibiting CD36 could be a crucial approach in cancer treatment [123]. Furthermore, the production of α -ketoglutarate (α -KG) through glutaminolysis enhances fatty acid oxidation (FAO) and epigenetic activation in the alternative (M2) activation of macrophages [124]. Impact of Fatty Acid Metabolism on Macrophage Responses It is suggested that the responses of macrophages are precisely regulated by fatty acid metabolism and epigenetic reprogramming. Metabolic adaptations in both tumor and immune cells within the tumor microenvironment (TME) likely arise due to changes in local nutrient availability. We will explore how these lipid metabolic processes affect cancer biology [15].

Lipid Metabolism in Cancer

Different lipid species exhibit contrasting effects on cancer growth and cell death, necessitating thorough mechanistic exploration. Cellular proliferation is a hallmark of all cancers, as fatty acids (FAs) are essential for synthesizing membranes and signaling molecules. Tumor cells accumulate significant lipids to support rapid growth;

however, they manage to evade toxicity from this apparent surplus of FAs. In fact, highly proliferative cancer cells often upregulate enzymes responsible for lipid and cholesterol biosynthesis, contributing to increased aggressiveness in certain cancers [125].

Emerging Insights into Cancer Fat Metabolism

Understanding how cancer metabolizes fats is a developing field of research. Many tumors prefer fatty acid oxidation (FAO) over glucose and glutamine. In various tissues, FAs are not the primary energy source; they are typically reserved for stressful conditions or nutrient scarcity, helping to restore metabolic balance. Notable metabolic re-wiring in FA metabolism has been observed in mouse hepatocellular carcinomas, primary human liver, and lung carcinomas. Cancer cells convert palmitate into the unusual fatty acid sapienate to aid in membrane biosynthesis [126]. Moreover, plasma membrane remodeling is crucial for oncogenic signaling. Lipids form the fundamental building blocks of cellular membranes and are vital for establishing barriers between subcellular compartments. Even minor alterations in the structure, composition, and interactions of lipids within cellular membranes can significantly impact biological functions. Advances in lipidomics have revealed the lipid species that constitute mammalian membranes, with major membrane lipids including glycerophospholipids (GPLs), sphingolipids, and sterols [127].

The composition of membrane lipids, their saturation levels, and their distribution within cells are often overlooked areas that are essential for maintaining organelle homeostasis, facilitating cell signaling, and managing nutrient and oxidative stress [51,128]. Additionally, Lysphosphatidylcholine acyltransferase 1 (LPCAT1) increases the saturated phosphatidylcholine content in the plasma membrane, further promoting tumor growth by activating oncogenic signals [129]. Interestingly, elevated levels of monounsaturated fatty acids (MUFAs) inhibit ferroptosis by competing with polyunsaturated fatty acids

(PUFAs) for incorporation into the membrane [116]. This specific lipid composition at the membrane plays a role in reducing reactive oxygen species (ROS) and lowers the amounts of oxidizable PUFA-containing phospholipids. This effect necessitates the activation of MUFAs by the long-chain family member of acyl-CoA synthetase (ACSL) 3 [130].

In a comparable manner, lysophosphatidylcholine acyltransferase 3 (LPCAT3) plays an essential role in incorporating polyunsaturated fatty acids (PUFAs) into phospholipids. A lack of LPCAT3 leads to considerable alterations in the composition of membrane phospholipids, especially marked by a significant decrease in arachidonic acid (AA), a PUFA present in these lipids [131]. ACSL4 is also involved in the localized release of AA within mitochondria, as it catalyzes the conversion of long-chain fatty acids (LCFAs) into their active form, acyl-CoA, which is essential for lipid synthesis. By producing arachidonoyl-CoA, ACSL4 mitigates the cytotoxic effects associated with elevated levels of unesterified AA, thereby raising the apoptotic threshold and enhancing the survival of castration-resistant prostate cancer cells. This suggests that the localized accumulation of PUFAs in mitochondria could result in membrane depolarization and the uncoupling of the electron transport chain (ETC), ultimately leading to heightened ROS production. Consequently, certain fatty acids may trigger ROS generation, endoplasmic reticulum (ER) stress, and ferroptosis. This highlights the importance of further research to clarify the influence of lipid properties on cancer [132] (Figure 9). This process enhances tumorigenesis by coordinating with PA, amino acids, and mTOR signaling, leading to increased fatty acid synthesis and SREBP transcription. De novo biosynthesis produces phospholipids and TAGs that promote cell proliferation and alter membrane lipid composition. Fatty acids entering the nucleus can activate cancer metastasis through nuclear receptors and PPAR. PUFAs can also trigger ROS-dependent ferroptosis. Different lipid signaling pathways in cancer may lead to either survival or cell death [15].




Figure 9: Lipid metabolism significantly influences cancer signaling, primarily through AKT phosphorylation, which starts lipid biosynthesis via ACY [15].

Lipid Toxicity in Cancer and Immune Cells

Tumors exploit pathways that typically protect normal cells from lipotoxicity as a strategy to navigate the challenging tumor microenvironment (TME). Cancer cells utilize autophagy to prevent the buildup of toxic cellular lipids and waste products by targeting intracellular components and organelles for degradation in the lysosomal compartment [133]. For instance, palmitate and other saturated fatty acids can induce apoptosis in breast cancer cells, while unsaturated FAs, like oleate, remain non-toxic to these cancer cells [134]. Additionally, cancer cells mitigate lipid toxicity by converting potentially harmful lipids-including FAs, diacylglycerol (DAG), cholesterol, and ceramide-into triglycerides (TGs), cholesterol esters, and acylceramides that can be stored in lipid droplets (LDs) [135]. The enzyme DGAT1 plays a role in this process by converting excess FAs into TGs and LDs, thereby shielding glioblastoma cells from oxidative damage [136]. Consequently, inhibiting DGAT1 leads to an influx of FAs into mitochondria for oxidation, causing an increase in reactive oxygen species (ROS), mitochondrial damage, cytochrome c release, and ultimately, apoptosis. Furthermore, blocking DGAT1 may redirect FAs into phospholipids, enhancing ferroptosis [137].

Ferroptosis in Cancer Cells

Ferroptosis [138], which also occurs in cancer cells, results from the lipid peroxidation of polyunsaturated fatty acids (PUFAs) found in phospholipids, generating various lipid hydroperoxides [139]. In gastric cancer cells, the expression of ELOVL5 and fatty acid desaturase 1 (FADS1) is upregulated, leading to increased sensitivity to ferroptosis. Notably, arachidonic acid (AA) supplementation can restore sensitivity to ferroptosis in these cells [140]. The enzyme GPX4 serves as a key regulator of ferroptosis, offering cellular protection by neutralizing lipid peroxides. The suppression of ferroptosis-by-ferroptosis suppressor protein 1 (FSP1) decreases coenzyme Q (CoQ), a lipophilic radical-trapping antioxidant that inhibits the spread of lipid peroxides in various cancer cells [141]. Recent research indicates that immunotherapy-activated CD8+ T cells boost ferroptosis-specific lipid peroxidation in tumor cells, suggesting that increased ferroptosis enhances the anti-tumor effectiveness of immunotherapy [99]. Thus, targeting biosynthetic and peroxisomal oxidation pathways may reveal new avenues for ferroptosis-mediated cancer therapies.

Summary

We explore the multifaceted world of lipids and their crucial roles in biological systems. Starting with the regulation of lipid digestion, the study highlights the pivotal functions of cholecystokinin (CCK) in stimulating digestive enzymes and bile secretion. It then delves into the diverse role's lipids play in cell biology and physiology, emphasizing their structural, signaling, and energy-storage functions. The classification of lipids sets the foundation, detailing the various types, including fatty acids, glycerol-based lipids, and complex lipids with distinct head groups. Understanding fatty acid and triacylglycerol me-

tabolism is essential, as these processes are central to energy balance and cellular function. The metabolism of complex lipids, cholesterol, and steroids further illustrates their influence on cellular processes and hormonal regulation. Key discussions include the cellular uptake and synthesis of fatty acids, pivotal for maintaining metabolic homeostasis. The diversity of phospholipids and their roles in membrane dynamics are also explored, alongside ceramide synthesis and its association with endoplasmic reticulum (ER) stress.

The research addresses lip toxicity, examining how excess lipid accumulation impacts organ systems such as adipose tissue, kidneys, liver, bone, and skeletal muscle, and its implications for metabolic regulation. The potential of fatty acid synthase (FASN) antagonists in cancer treatment is highlighted, offering insights into targeting lipid metabolism in oncological contexts. Lipid interactions with the immune system and their significance in cardiovascular health are discussed, underlining the complexity of lipid roles across physiological systems. The study concludes by examining emerging insights into cancer fat metabolism and the intriguing phenomenon of ferroptosis in cancer cells, providing a window into future therapeutic strategies.

Conclusion

In conclusion, this research provides a comprehensive overview of the intricate roles that lipids play in various biological processes and their profound impact on health and disease. From the fundamental aspects of lipid digestion and metabolism to their involvement in cell signaling and structural integrity, lipids are indispensable for maintaining physiological balance. The exploration of lipid metabolism reveals critical insights into energy homeostasis and the intricate mechanisms by which lipids influence hormonal and cellular regulation. The study further sheds light on the pathological consequences of lipid dysregulation, such as lip toxicity and its effects on organ function, emphasizing the need for targeted approaches to manage metabolic disorders. The potential therapeutic applications of modulating lipid pathways are particularly promising in the context of cancer treatment and immune regulation. By targeting specific enzymes and pathways, such as fatty acid synthase, new strategies could emerge to combat cancer and other lipid-related diseases. Overall, this research underscores the necessity of continued investigation into lipid biology, as understanding these complex molecules offers valuable opportunities for the development of innovative therapeutic interventions. As research progresses, the evolving landscape of lipid science promises to unveil even more profound insights into the vital role's lipids play in health and disease.

References

1. Harvey R, Ferrier D (2008) Lippincott's Illustrated Reviews: Biochemistry (5th Edn.),.
2. Kupikowska Stobba B, Niu H, Kłodová I, Agregán R, Lorenzo J M, et al. (2025) Controlled lipid digestion in the development of functional and personalized foods for a tailored delivery of dietary fats. Food Chem 466: 142151.

3. Holmes RS, Cox LA, VandeBerg JL (2010) Comparative studies of mammalian acid lipases: Evidence for a new gene family in mouse and rat (Lipo). *Comp Biochem Physiol Part D Genomics Proteomics* 5(3): 217-226.
4. Cerk I K, Wechselberger L, Oberer M (2018) Adipose Triglyceride Lipase Regulation: An Overview. *Curr Protein Pept Sci* 19(2): 221-233.
5. McQuilken SA (2021a) Digestion and absorption. *Anaes & Inten Care Med* 22(5): 336-338.
6. McQuilken SA (2021b) The mouth, stomach and intestines. *Anaes & Inten Care Med* 22(5): 330-335.
7. Golding M, Wooster T J (2010) The influence of emulsion structure and stability on lipid digestion. *Curr Opin in Coll & Inter Sci* 15(1-2): 90-101.
8. Sun C, Zhang M, Zhang X, Li Z, Guo Y, et al. (2022) Design of protein-polysaccharide multi-scale composite interfaces to modify lipid digestion. *Tren in Food Sci & Tech* 127(10): 38-48.
9. Kumar A, Chauhan S (2021) Pancreatic lipase inhibitors: The road voyaged and successes. *Lif Sci* 271: 119115.
10. McClements D J (2018) The biophysics of digestion: Lipids. *Curr Opin in Food Sci* 21: 1-6.
11. Okonkwo O, Zezoff D, Adeyinka A (2023) *Biochemistry, Cholecystokinin*. Treasure Island (FL): StatPearls Publishing.
12. Ma J, Dankulich Nagrudny L, Lowe G (2013) Cholecystokinin: an excitatory modulator of mitral/tufted cells in the mouse olfactory bulb. *PLoS One* 8(5): e64170.
13. Beinfeld M C (2001) An introduction to neuronal cholecystokinin. *Pep-tides* 22(8): 1197-200.
14. Yang K, Cheng H, Gross R W, Han X (2009) Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. *Anal Chem* 81(11): 4356-4368.
15. Yoon H, Shaw J H, Haigis M C, Greka A (2021) Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. *Mol Cell Elsevier* 81(18): 3708-3730.
16. Musunuru K, Kathiresan S (2016) Surprises from genetic analyses of lipid risk factors for atherosclerosis. *Circ Res* 118: 579-585.
17. Musunuru K, Kathiresan S (2019) Genetics of common, complex coronary artery disease. *Cell* 177(1): 132-145.
18. Beloribi Djefafli S, Vasseur S, Guillaumond F (2016) Lipid metabolic reprogramming in cancer cells. *Oncogenesis* 5: e189.
19. Lytrivi M, Castell AL, Poitout V, Cnop M (2020) Recent insights into mechanisms of b-cell lipo- and glucolipotoxicity in type 2 diabetes. *J Mol Biol* 432(5): 1514-1534.
20. Sharma R B, Alonso L C (2014) Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well?. *Curr Diab Rep* 14(6): 492.
21. Lee Y, Hirose H, Ohneda M, Johnson J H, McGarry J D, et al. (1994) Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. *Proc Natl Acad Sci* 91(23): 10878-10882.
22. Goldberg I J, Trent C M, Schulze P C (2012) Lipid metabolism and toxicity in the heart. *Cell Metab* 15(6): 805-812.
23. Raghu P (2020) Functional diversity in a lipidome. *Proc Natl Acad Sci* 117(21): 11191-11193.
24. Fahy E, Cotter D, Sud M, Subramaniam S (2011) Lipid classification, structures and tools. *Biochim Biophys Acta* 1811(11): 637-647.
25. Janson LW, Tischler ME (2024) McGraw Hill, The Big Picture: Medical Biochemistry.
26. Murphy RC, Leiker TJ, Barkley RM (2011) Glycerolipid and cholesterol ester analyses in biological samples by mass spectrometry. *Biochim Biophys Acta* 1811(11): 776-783.
27. Spector AA, Kim HY (2015) Discovery of essential fatty acids. *J Lipid Res* 56(1): 11-21.
28. de Carvalho CCCR, Caramujo MJ (2018) The various roles of fatty acids. *Molecules* 23(10): 2583.
29. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I κ B α . *Diabetes* 51(7): 2005-2011.
30. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab* 7(1): 45-56.
31. Wajner M, Amaral A U (2015) Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. *Biosci Rep* 36: e00281.
32. Kuroki Y, Akino T (1991) Pulmonary surfactant protein A (SP-A) specifically binds dipalmitoylphosphatidylcholine. *J Biol Chem* 266(5): 3068-3073.
33. Cui D, Yu X, Guan Q, Shen Y, Liao J, et al. (2025) Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets. *Mol Biomed* 6(1): 72.
34. Kazantzis M, Stahl A (2012) Fatty acid transport proteins, implications in physiology and disease. *Biochim Biophys Acta* 1821(5): 852-857.
35. Schwenk RW, Holloway GP, Luiken JFP, Bonen A, Glatz J FC, et al. (2010) Fatty acid transport across the cell membrane: regulation by fatty acid transporters. *Prostaglandins Leukot Essent Fatty Acids* 82(4-6): 149-154.
36. Stahl A, Gimeno RE, Tartaglia LA, Lodish H F (2001) Fatty acid transport proteins: a current view of a growing family. *Trends Endocrinol Metab* 12(6): 266-273.
37. Su X, Abumrad N A (2009) Cellular fatty acid uptake: a pathway under construction. *Trends Endocrinol Metab* 20(2): 72-77.
38. Birsoy K, Wang T, Chen WW, Freinkman E, Abu Remeileh M, et al. (2015) An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. *Cell* 162(3): 540-551.
39. Cechetto JD, Sadacharan SK, Berk PD, Gupta RS (2002) Immunogold localization of mitochondrial aspartate aminotransferase in mitochondria and on the cell surface in normal rat tissues. *Histol Histopathol* 17(2): 353-364.
40. Roche CM, Blanch HW, Clark DS, Glass NL (2013) Physiological role of Acyl coenzyme A synthetase homologs in lipid metabolism in *Neurospora crassa*. *Eukaryot Cell* 12(9): 1244-1257.
41. Coe NR, Simpson MA, Bernlohr DA (1999) Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. *J Lipid Res* 40(5): 967-972.
42. Schaffer J E, Lodish H F (1994) Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. *Cell* 79(3): 427-436.
43. Zaidi N, Swinnen J V, Smans K (2012) ATP-citrate lyase: a key player in cancer metabolism. *Cancer Res* 72(15): 3709-3714.
44. Zhou W, Tu Y, Simpson P J, Kuhajda FP (2009) Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. *Oncogene* 28(33): 2979-2987.

45. Bogie JFJ, Grajchen E, Wouters E, Corrales AG, Dierckx T, et al. (2020) Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. *J Exp Med* 217: e20191660.
46. Jakobsson A, Westerberg R, Jakobsson A (2006) Fatty acid elongases in mammals: their regulation and roles in metabolism. *Prog Lipid Res* 45(3): 237-249.
47. Stone SJ, Levin MC, Farese RV (2006) Membrane topology and identification of key functional amino acid residues of murine acyl-CoA: diacylglycerol acyltransferase-2. *J Biol Chem* 281(52): 40273-40282.
48. Cases S, Smith S J, Zheng Y W, Myers H M, Lear S R, et al. (1998) Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. *Proc Natl Acad Sci* 95(22): 13018-13023.
49. Dihingia A, Bordoloi J, Dutta P, Kalita J, Manna P, et al. (2018) Hexaneisopropanolic extract of tungrymbai, a North-East Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP/FAS/ ACC/HMGCR and PPAR α /CPT1A/UCP2 pathways. *Sci Rep* 8(1): 10021.
50. Aregger M, Lawson KA, Billmann M, Costanzo M, Tong AHY, et al. (2020) Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism. *Nat Metab* 2(6): 499-513.
51. Röhrig F, Schulze A (2016) The multifaceted roles of fatty acid synthesis in cancer. *Nat Rev Cancer* 16(11): 732-749.
52. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, et al. (2013) Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. *Cancer Metab* 1(1): 3.
53. Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, et al. (2015) SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. *Oncogene* 34(40): 5128-5140.
54. Zhang Y, Li C, Hu C, Wu Q, Cai Y, et al. (2019) Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1. *EMBO Rep* 20(10): e48115.
55. Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM, et al. (2021) Lipid metabolism in cancer: New perspectives and emerging mechanisms. *Dev Cell* 56(10): 1363-1393.
56. Fagone P, Jackowski S (2009) Membrane phospholipid synthesis and endoplasmic reticulum function. *J Lipid Res* 50(Suppl): S311-S316.
57. Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. *Br J Cancer* 122(1): 4-22.
58. Anaokar S, Kodali R, Jonik B, Renne MF, Brouwers JFHM, et al. (2019) The glycerophosphocholine acyltransferase Gpc1 is part of a phosphatidylcholine (PC)-remodeling pathway that alters PC species in yeast. *J Biol Chem* 294(4): 1189-1201.
59. Vance JE (2014) MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochim Biophys Acta* 1841(4): 595-609.
60. Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* 296(5573): 1655-1657.
61. Wigger D, Gulbins E, Kleuser B, Schumacher F (2019) Monitoring the sphingolipid de novo synthesis by stable-isotope labeling and liquid chromatography-mass spectrometry. *Front Cell Dev Biol* 7: 210.
62. Wagner R, Stubiger G, Veigel D, Wuczkowski M, Lanzerstorfer P, et al. (2017) Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. *Oncotarget* 8(7): 11600-11613.
63. Du W, Zhang L, BrettMorris A, Aguila B, Kerner J, et al. (2017) HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. *Nat Commun* 8(1): 1769.
64. Pereira ER, Frudd K, Awad W, Hendershot LM (2014) Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). *J Biol Chem* 289(6): 3352-3364.
65. Qiu B, Ackerman D, Sanchez D J, Li B, Ochocki J D, et al. (2015) HIF2 α -dependent lipid storage promotes endoplasmic reticulum homeostasis in clearcell renal cell carcinoma. *Cancer Discov* 5(6): 652-667.
66. Olzmann J A, Carvalho P (2019) Dynamics and functions of lipid droplets. *Nat Rev Mol Cell Biol* 20(3): 137-155.
67. Mueller DR, Voshol H, Waldt A, Wiedmann B, Van Oostrum J, et al. (2007) LC-MALDI MS and MS/MS—an efficient tool in proteome analysis. In *Subcellular Proteomics*, E. Bertrand and M. Faupel, eds 43: 355-380.
68. Giro'Perafita A, Palomeras S, Lum DH, Blancafort A, Vin'as G, et al. (2016) Preclinical evaluation of fatty acid synthase and EGFR inhibition in triple-negative breast cancer. *Clin Cancer Res* 22(18): 4687-4697.
69. Kumar Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM, et al. (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. *Cancer Res* 63(1): 132-139.
70. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, et al. (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. *Proc Natl Acad Sci* 101(29): 10715-10720.
71. Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, et al. (2021) Fatty acid synthesis is required for breast cancer brain metastasis. *Nat Cancer* 2(4):414-428. Epub. Erratum in: *Nat Cancer* 2(11): 1243.
72. Carbonetti G, Wilpshaar T, Kroonen J, Studholme K, Converso C, et al. (2019) FABP5 coordinates lipid signaling that promotes prostate cancer metastasis. *Sci Rep* 9(1): 18944.
73. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen J V, et al. (2002) Role of the phosphatidylinositol 30 -kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. *Cancer Res* 62(3): 642-646.
74. German NJ, Yoon H, Yusuf RZ, Murphy JP, Finley LWS, et al. (2016) PHD3 loss in cancer enables metabolic reliance on fatty acid oxidation via deactivation of ACC2. *Mol Cell* 63(6): 1006-1020.
75. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, et al. (2002) Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. *J Appl Physiol* 1985(92): 2475-2482.
76. Yoon H, Spinelli JB, Zaganjor E, Wong SJ, German NJ, et al. (2020) PHD3 loss promotes exercise capacity and fat oxidation in skeletal muscle. *Cell Metab* 32(2): 215-228.e7.
77. Michel CI, Holley CL, Scruggs BS, Sidhu R, Brookheart RT, et al. (2011) Small Nucleolar RNAs U32a, U33, and U35a Are Critical Mediators of Metabolic Stress. *Cell Meta Elsevier* 14(1): 33-44.
78. Felix J B, Cox AR, Hartig SM (2021) Acetyl-CoA and metabolite fluxes regulate white adipose tissue expansion. *Trends Endocrinol Metab* 32(5): 320-332.
79. Deshmukh AS, Peijs L, Beaudry JL, Jespersen NZ, Nielsen CH, et al. (2019) Proteomics-based comparative mapping of the secretomes of human

- brown and white adipocytes reveals EPDR1 as a novel batokine. *Cell Metab* 30(5): 963-975.e7.
80. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, et al. (2005) Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. *J Biol Chem* 280(37): 32317-32325.
 81. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, et al. (2007) Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. *J Am Soc Nephrol* 18(10): 2715-2723.
 82. Wang H, Franco F, Tsui YC, Xie X, Trefny MP, et al. (2020) CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. *Nat Immunol* 21(3): 298-308.
 83. Bobulescu IA (2010) Renal lipid metabolism and lipotoxicity. *Curr Opin Nephrol Hypertens* 19(4): 393-402.
 84. Balaban R S, Mandel L J (1988) Metabolic substrate utilization by rabbit proximal tubule. An NADH fluorescence study. *Am J Physiol* 254(3 Pt 2): F407-F416.
 85. Gullans SR, Brazy PC, Mandel LJ, Dennis VW (1984) Stimulation of phosphate transport in the proximal tubule by metabolic substrates. *Am J Physiol* 247(4 Pt 2): F582-F587.
 86. Uchida S, Endou H (1988) Substrate specificity to maintain cellular ATP along the mouse nephron. *Am J Physiol* 255(5 Pt 2): F977-F983.
 87. Mori Y, Ajay AK, Chang JH, Mou S, Zhao H, et al. (2021) KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic kidney disease. *Cell Metab* 33(5): 1042-1061.e7.
 88. Hajeyah AA, Griffiths WJ, Wang Y, Finch AJ, O'Donnell VB, et al. (2020) The biosynthesis of enzymatically oxidized lipids. *Front Endocrinol. (Lausanne)* 11: 591819.
 89. Sun L, Halaihel N, Zhang W, Rogers T, Levi M, et al. (2002) Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. *J Biol Chem* 277(21): 18919-18927.
 90. Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. *Clin J Am Soc Nephrol* 12(12): 2032-2045.
 91. DAGati VD, Chagnac A, de Vries APJ, Levi M, Porrini E, et al. (2016) Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. *Nat Rev Nephrol* 12(8): 453-471.
 92. Sidhom EH, Kim C, Kost Alimova M, Ting MT, Keller K, et al. (2021) Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ deficiency kidney disease. *J Clin Invest* 131(5): e141380.
 93. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, et al. (2014) Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nat Cell Biol* 16(12): 1180-1191.
 94. Fu Y, Sun Y, Wang M, Hou Y, Huang W, et al. (2020) Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. *Cell Metab* 32(6): 1052-1062.e8.
 95. Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, et al. (2016) Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. *Gastroenterology* 151(4): 733-746.e12.
 96. Baratta F, Pastori D, Ferro D, Carluccio G, Tozzi G, et al. (2019) Reduced lysosomal acid lipase activity: a new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?. *World J Gastroenterol* 25(30): 4172-4180.
 97. Mukai T, Egawa M, Takeuchi T, Yamashita H, Kusudo T, et al. (2017) Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. *FEBS Open Bio* 7(7): 1009-1016.
 98. Wang Y, Tang K, Zhang W, Guo W, Wang Y, et al. (2019) Fatty acid-binding protein 1 increases steer fat deposition by facilitating the synthesis and secretion of triacylglycerol in liver. *PLoS ONE* 14: e0214144.
 99. Zhou P, Santoro A, Peroni OD, Nelson AT, Saghatelian A, et al. (2019) PAH-SAs enhance hepatic and systemic insulin sensitivity through direct and indirect mechanisms. *J Clin Invest* 129(10): 4138-4150.
 100. Syed I, Lee J, Moraes Vieira PM, Donaldson CJ, Sontheimer A, et al. (2018) Palmitic acid hydroxystearic acids activate GPR40, which is involved in their beneficial effects on glucose homeostasis. *Cell Metab* 27(2): 419-427.e4.
 101. Kushwaha P, Wolfgang M J, Riddle R C (2018) Fatty acid metabolism by the osteoblast. *Bone* 115: 8-14.
 102. Løvsletten NG, Bakke SS, Kase ET, Ouwens DM, Thoresen GH, et al. (2018) Increased triacylglycerol-fatty acid substrate cycling in human skeletal muscle cells exposed to eicosapentaenoic acid. *PLoS ONE* 13: e0208048.
 103. Berliner JA, Leitinger N, Tsimikas S (2009) The role of oxidized phospholipids in atherosclerosis. *J Lipid Res* 50 (Suppl): S207-S212.
 104. Binder CJ, PapacMilicevic N, Witztum JL (2016) Innate sensing of oxidation-specific epitopes in health and disease. *Nat Rev Immunol* 16(8): 485-497.
 105. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. *Nat Immunol* 12(3): 204-212.
 106. Jelenik T, Flo'gel U, A'lvarez Herna'ndez E, Scheiber D, Zweck E, et al. (2018) Insulin resistance and vulnerability to cardiac ischemia. *Diabetes* 67(12): 2695-2702.
 107. Fang X, Wang H, Han D, Xie E, Yang X, et al. (2019) Ferroptosis as a target for protection against cardiomyopathy. *Proc Natl Acad Sci* 116(7): 2672-2680.
 108. Park TJ, Park JH, Lee GS, Lee JY, Shin JH, et al. (2019) Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes. *Cell Death Dis* 10(11): 835.
 109. Bagchi AK, Surendran A, Malik A, Jassal DS, Ravandi A, et al. (2020) IL-10 attenuates OxPCs-mediated lipid metabolic responses in ischemia reperfusion injury. *Sci Rep* 10(1): 12120.
 110. Meeusen JW, Donato LJ, Jaffe AS (2017) Lipid biomarkers for risk assessment in acute coronary syndromes. *Curr Cardiol Rep* 19(6): 48.
 111. Hadas Y, Vincek AS, Youssef E, Zak MM, Chepurko E, et al. (2020) Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction. *Circulation* 141(11): 916-930.
 112. Arana L, Gangoiti P, Ouro A, Trueba M, Antonio Gómez Muñoz, et al. (2010) Ceramide and ceramide 1-phosphate in health and disease. *Lipids Health Dis* 9: 15.
 113. Klevstig M, Arif M, Mannila M, Svedlund S, Mardani I, et al. (2019) Cardiac expression of the microsomal triglyceride transport protein protects the heart function during ischemia. *J Mol Cell* 37: 1-8.
 114. Neubauer S (2007) The failing heart—an engine out of fuel. *N Engl J Med* 356(11): 1140-1151.
 115. Finck B N, Han X, Courtois M, Aimond F, Nerbonne J M, et al. (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. *Proc Natl Acad Sci* 100(3): 1226-1231.

116. Roberts L D, Koulman A, Griffin J L (2014) Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. *Lan Diab Endo* 2(1): 65-75.
117. Nakamura M, Liu T, Husain S, Zhai P, Warren J S, et al. (2019) Glycogen synthase kinase-3 α promotes fatty acid uptake and lipotoxic cardiomyopathy. *Cell Metab* 29(5): 1119-1134.e12.
118. Simopoulos A P (2002) Omega-3 fatty acids in inflammation and autoimmune diseases. *J Am Coll Nutr* 21(21): 495-505.
119. Marton LT, Goulart RA, Carvalho ACA, Barbalho SM (2019) Omega fatty acids and inflammatory bowel diseases: an overview. *Int J Mol Sci* 20(19): 4851.
120. Sulciner M L, Serhan C N, Gilligan MM, Mudge DK, Chang J, et al. (2018) Resolvins suppress tumor growth and enhance cancer therapy. *J Exp Med* 215(1): 115-140.
121. Zhang Y, Kurupati R, Liu L, Zhou X Y, Zhang G, et al. (2017) Enhancing CD8 $^{+}$ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. *Cancer Cell* 32(3): 377-391.e9.
122. Bader J E, Voss K, Rathmell J C (2020) Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. *Mol Cell* 78(6): 1019-1033.
123. Huang S CC, Everts B, Ivanova Y, OSullivan D, Nascimento M, et al. (2014) Cellintrinsic lysosomal lipolysis is essential for alternative activation of macrophages. *Nat Immunol* 15(9): 846-855.
124. Liu PS, Wang H, Li X, Chao T, Teav T, et al. (2017b) aketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. *Nat Immunol* 18(9): 985-994.
125. Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, et al. (2019) Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. *Nature* 566(7744): 403-406.
126. Harayama T, Riezman H (2018) Understanding the diversity of membrane lipid composition. *Nat Rev Mol Cell Biol* 19(5): 281-296.
127. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, et al. (2010) De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. *Cancer Res* 70(20): 8117-8126.
128. Bi J, Ichu T A, Zanca C, Yang H, Zhang W, et al. (2019) Oncogene amplification in growth factors signaling pathways renders cancers dependent on membrane lipid remodeling. *Cell Metab* 30(3): 525-538.e8.
129. Magtanong L, Ko P J, To M, Cao J Y, Forcina G C, et al. (2019) Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. *Cell Chem Biol* 26(3): 420-432.e9.
130. Hashidate Yoshida T, Harayama T, Hishikawa D, Morimoto R, Hamano F, et al. (2015) Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport. *eLife* 4: e06328.
131. Kuwata H, Hara S (2019) Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism. *Prostaglandins Other Lipid Mediat* 144: 106363.
132. Poillet Perez L, White E (2019) Role of tumor and host autophagy in cancer metabolism. *Genes Dev* 33(11-12): 610-619.
133. Hardy S, El Assaad W, Przybytkowski E, Joly E, Prentki M, et al. (2003) Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. *J Biol Chem* 278(34): 31861-31870.
134. Senkal C E, Salama M F, Snider A J, Allopenna J J, Rana N A, et al. (2017) Ceramide is metabolized to acylceramide and stored in lipid droplets. *Cell Metab* 25(3): 686-697.
135. Dierge E, Debock E, Guilbaud C, Corbet C, Mignolet E, et al. (2021) Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. *Cell Metab* 33(8): 1701-1715.e5.
136. Cheng X, Geng F, Pan M, Wu X, Zhong Y, et al. (2020) Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. *Cell Metab* 32(2): 229-242.e8.
137. Stockwell B R, Friedmann Angeli J, Pedro Bayir H, Bush A I, Conrad M, et al. (2017) Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell* 171(2): 273-285.
138. Kuhn H, Banthiya S, van Leyen K (2015) Mammalian lipoxygenases and their biological relevance. *Biochim Biophys Acta* 1851(4): 308-330.
139. Lee J Y, Nam M, Son H Y, Hyun K, Jang S Y, et al. (2020) Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. *Proc Natl Acad Sci USA* 117(51): 32433-32442.
140. Bersuker K, Hendricks J M, Li Z, Magtanong L, Ford B, et al. (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 575(7784): 688-692.
141. Doll S, Freitas F P, Shah R, Aldrovandi M, da Silva M C, et al. (2019) FSP1 is a glutathione-independent ferroptosis suppressor. *Nature* 575(7784): 693-698.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2026.65.010128

Alber Fares. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>**Assets of Publishing with us**

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>